|Articles|August 4, 2004

Start-up Alimera Sciences receives funding for ophthalmic products

Series A financing worth $26.75 million will be used by Alimera Sciences Inc. for acquisition and continued development of the company's ophthalmic pharmaceutical pipeline, along with commercialization of the company's over-the-counter ophthalmic products.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME